Topical Finasteride Minoxidil Formulation for Alopecia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for androgenic alopecia, such as Minoxidil and Finasteride, have limitations including significant side effects and limited efficacy, with Finasteride's oral use posing risks and Minoxidil's mechanism of action not fully understood, necessitating a more effective and safer topical formulation.
Innovation Solution
A topical formulation combining Finasteride with silicones and Minoxidil, potentially incorporating retinol, to enhance hair growth with reduced systemic side effects, using an anhydrous vehicle and porous polymers for slow release to improve transdermal penetration and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If Finasteride is used orally to treat androgenic alopecia, then hair growth is stimulated, but significant side effects occur including impotence, erection failure, decreased libido, and gynecomastia
Solution Approach 1:
The patent applies Finasteride topically to the scalp rather than systemically through oral administration. This localized application ensures that the drug acts only at the site of hair growth, stimulating hair growth in the scalp while avoiding systemic circulation that causes impotence, erection failure, decreased libido, and gynecomastia.
Solution Approach 2:
The patent uses a topical formulation system as an intermediary to deliver Finasteride to the scalp. This formulation acts as a mediator that allows the drug to penetrate the scalp and reach the hair bulb without entering the systemic circulation, thus achieving hair growth stimulation while preventing systemic side effects.
2Object-generated harmful factors
If Finasteride is applied topically to reduce DHT formation, then hair growth is stimulated without systemic side effects, but penetration to the hair bulb level is insufficient
Solution Approach 1:
The patent modifies the physical and chemical parameters of the Finasteride molecule and its formulation to enhance penetration. This includes adjusting the molecular properties of Finasteride and the formulation characteristics (such as using anhydrous vehicles and porous polymers) to improve transdermal penetration and ensure reliable delivery to the hair bulb level.
Solution Approach 2:
The patent incorporates porous polymers in the topical formulation to enhance the penetration of Finasteride through the scalp. The porous structure provides pathways that facilitate drug permeation while maintaining controlled release, ensuring reliable delivery to the hair bulb without causing systemic side effects.
3Productivity
If Minoxidil is used topically to treat alopecia, then hair growth is stimulated through vasodilation and potassium channel opening, but the mechanism of action is not fully clarified and response is limited to 40% of individuals
Solution Approach 1:
The patent combines Finasteride and Minoxidil in a single topical formulation. This combination merges the DHT inhibition mechanism of Finasteride with the vasodilation and potassium channel opening mechanism of Minoxidil, providing synergistic effects that enhance hair growth stimulation and expand the responsive population beyond the 40% limit of Minoxidil alone.
Solution Approach 2:
The patent creates a composite topical formulation that integrates multiple active ingredients (Finasteride, Minoxidil, and potentially retinol) with specific carriers and adjuvants. This composite system enhances the overall efficacy by combining different mechanisms of action while improving delivery and penetration characteristics.
4Object-affected harmful factors
If Finasteride is used at 1 mg daily for oral treatment, then teratogenesis risk is reduced, but hormonal function is not completely prevented and limited efficacy is achieved
Solution Approach 1:
The patent applies Finasteride locally to the scalp through topical formulation rather than systemically through oral administration. This localized application allows the drug to inhibit 5α-reductase specifically at the scalp level, providing more effective hormonal function inhibition in the target area while maintaining safety by avoiding systemic circulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of Finasteride and Minoxidil in a silicone-based formulation significantly increases hair growth efficacy, reduces side effects, and improves hair properties like softness and shine, as demonstrated by clinical studies, providing a safer and more effective treatment for both men and women.
Implementation Method 1
This compound is an inhibitor of 5a: -reductase types II and III, which prevents the transformation of testosterone into DHT, significantly reducing the concentration of DHT in the scalp
Implementation Method 2
it is postulated that it works by producing local vasodilation and opening the cellular potassium channels. This allows the blood to containing oxygen and nutritional elements, it reaches the hair follicle more easily
Implementation Method 3
Finasteride could be applied topically and penetrate the scalp at the level of the hair bulb in order to locally reduce the formation of DHT
Data Source
AI summary
The present invention relates to a topical formulation intended to be used for the treatment of androgenic or androgenetic baldness is men and women, with reduced side effects, especially with fewer collateral effects in the female population. The topical formulation comprises 0.01% to 10% by weight of Finasteride and a concentration of 1% to 5% by weight of Minoxidil in its free form or in an inert porous polymer. The combination of Finasteride and Minoxidil provides a synergistic effect against baldness. The formulation also comprises 0.15% by weight of retinol and is suitable for being applied to the scalp of the patient that requires it.